Project Grant R21CA283355
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$404K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This federal Project Grant award from the National Institutes of Health's Cancer Treatment Research program (CFDA 93.395) provides $610,783 to The Methodist Hospital Research Institute (HMRI) in Houston, TX to develop an innovative gene delivery approach that modulates the tumor microenvironment and enhances antigen-specific anti-tumor immunity. The project aims to leverage recombinant adenovirus technology to selectively deliver a suicide gene (HSV-TK) and an immune checkpoint antibody...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University provides $622,329 to conduct research aimed at modulating the growth, progression, and metastasis of triple-negative breast cancer (TNBC) by inhibiting the MDA-9 protein. The key objectives are to: 1) formulate a small molecule inhibitor of MDA-9 called PDZ1I-Nano for clinical use and characterize its non-cell-autonomous anti-tumor effects, particularly on...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $211,125 to Embiosys Inc. to develop a wearable, non-invasive treatment device for metastatic triple-negative breast cancer (TNBC). The goal is to combine this novel induced electric field (IEF) therapy with standard-of-care chemotherapies to improve outcomes for TNBC patients, particularly those who are ineligible for chemo-immunotherapy combinations. The 2-year project,...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $218,089 to the University of California, Santa Barbara to develop and evaluate a novel immunotherapy approach using Rac-enhanced chimeric antigen receptor macrophages (RACE-CAR-M) to target triple-negative breast cancer (TNBC). The key products and services to be delivered include: Evaluating the specificity, efficacy, and impact on angiogenesis of anti-CSPG4 RACE-CAR-Ms using...
This $154,142 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Baylor College of Medicine to examine the link between the molecular profile of triple-negative breast cancer (TNBC) and the origin and function of intratumoral macrophages. The overarching objective is to elucidate how the distinct molecular landscapes of TNBC subtypes impact the enrichment of macrophages from different origins (tissue-resident vs....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research to develop and evaluate Antibody-Drug Conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The total funding amount is $215,311 for the period from March 10, 2025 to February 28, 2027. The key objectives are to generate GPR56-targeted ADCs, assess their efficacy and safety in preclinical TNBC models, and evaluate the...
This $647,632 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the University of California, Los Angeles (UCLA) to develop and evaluate "TNF-ALPHA-ARMED" T-cell receptor (TCR) and chimeric antigen receptor (CAR) vectors for enhancing adoptive cell therapy against solid tumors. The key objectives are to: 1) assess the impact of co-delivering transgenic TNF-alpha with TCR or CAR constructs on T-cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on activating TFEB, a transcription factor, to enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The $400,000 award supports two specific aims: 1) evaluating the toxicity and pharmacokinetics of the TFEB activator compound USCYL01 in vitro and in vivo, and 2) testing USCYL01 as an agent to enhance the efficacy of immune checkpoint inhibitor (ICI) plus...
The National Cancer Institute awarded Immunova Therapeutics LLC a $1,001,029 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a CD4+ T cell receptor (TCR)-engineered immunotherapy for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) generate a GMP-grade Master Cell Bank and viral particles for the IMT-422 (CD4 TCR-STEM T cell) product, and 2) evaluate the pharmacokinetics, biodistribution, and toxicity of the IMT-422...